东诚药业：拟分拆子公司蓝纳成赴港上市，规模不超25%

Core Viewpoint - Dongcheng Pharmaceutical plans to spin off its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., for a listing on the Hong Kong Stock Exchange [1] Summary by Relevant Sections - Spin-off Details - The supervisory board of Dongcheng Pharmaceutical has approved the proposal for the spin-off of Yantai Lannacheng Biotechnology [1] - The initial scale of the offering will not exceed 25% of the total share capital after the issuance [1] - An overall coordinator is granted an over-allotment option of up to 15% of the initial H-share offering size [1] - The spin-off listing plan is subject to approval by the company's shareholders' meeting [1]